Featured Research

from universities, journals, and other organizations

HIV/AIDS Researcher Announces New Protease Inhibitor; Holds Promise As A Medication With Fewer Side Effects And Once-Daily Dosing

Date:
February 7, 2001
Source:
University Of Southern California
Summary:
A new protease inhibitor has been shown to be safe, tolerable and effective at holding off HIV in HIV-positive patients with only one dose a day, according to data presented by a University of Southern California researcher at the Eighth Conference on Retroviruses and Opportunistic Infections.

Feb. 5, 2001 -- A new protease inhibitor has been shown to be safe, tolerable and effective at holding off HIV in HIV-positive patients with only one dose a day, according to data presented today by a University of Southern California researcher at the Eighth Conference on Retroviruses and Opportunistic Infections.

The drug—known as BMS-232632—differs from previous protease inhibitors in part because those drugs have required patients to adhere to complex dosing schedules. Doctors commonly prescribe one of a variety of protease inhibitors, in partnership with drugs called nucleoside analogs, in a pharmaceutical battle plan to combat HIV.

"Our study showed that BMS-232632 is a potent protease inhibitor that is well tolerated and can be used safely in combination with other anti-HIV therapies," said Kathleen Squires, M.D., associate professor of medicine at the Keck School of Medicine of USC. "This new drug offers patients once-daily dosing, and the additional benefit of a low pill burden."

The drug remains active in the bloodstream for longer than other protease inhibitors, making it effective over a longer period and at a lower dose than other protease inhibitors. Squires was a principal investigator for the first and second phases of the study, which was conducted at more than two dozen sites in numerous countries on three continents. The double-blind randomized 48 week-long study examined the safety and effectiveness of BMS-232632 (paired with two other common anti-HIV drugs known as stavudine and didanosine) compared to a currently available protease inhibitor called nelfinavir (also paired with the same two anti-HIV drugs).

Data from 480 patients showed comparable effectiveness of BMS-232632, at doses five to 10 times lower than nelfinavir, Squires said. The drug was just as effective as nelfinavir in reducing the reproduction of the HIV virus and increasing the number of virus-fighting immune cells, called CD4 T-cells, in the body.

Interestingly, and potentially important for HIV-positive patients, the new drug appears to have no effect on cholesterol and triglycerides, Squires said. Today’s commonly used protease inhibitors are associated with increases in cholesterol and triglycerides, which are known to increase the risk of cardiovascular problems.

The study also showed the drug produced fewer side effects. About 17 percent of patients taking BMS-232632 in the study experienced diarrhea, for example, far fewer than the 55 percent of patients taking the other protease inhibitor. The most common side effect seen from taking BMS-232632 was hyperbilirubinemia, or too much bilirubin in the blood. Although the condition can lead to jaundice in its extreme, the cases found in the study were only detectable through lab tests and were easily managed through a small reduction in the dose.

"It remains to be seen whether BMS-232632 has the potential to avoid other long-term complications such as lipodystrophy," Squires added.

Lipodystrophy is a common problem linked to protease inhibitors in which a patient’s belly swells or a pad of fat may grow behind the neck, while the arms, legs and face become gaunt. Because the drug also has been shown to work against HIV strains that already have grown resistant to other protease inhibitors, researchers hope to pursue its potential as a back-up protease inhibitor when patients fail their current regimen.

That will become increasingly important over time as patients on highly active antiretroviral therapy, or HAART, see the virus become resistant to the drugs they are currently taking—requiring a switch to new drugs.

Squires conducted the research at the University of Alabama at Birmingham before moving to USC. Squires and other investigators will soon begin phase III clinical trials in a number of other studies, in cooperation with the drug’s maker, Bristol-Myers Squibb, to further test effectiveness. Squires will soon begin the phase III testing at USC on the effectiveness of a 400 mg dose of the drug.


Story Source:

The above story is based on materials provided by University Of Southern California. Note: Materials may be edited for content and length.


Cite This Page:

University Of Southern California. "HIV/AIDS Researcher Announces New Protease Inhibitor; Holds Promise As A Medication With Fewer Side Effects And Once-Daily Dosing." ScienceDaily. ScienceDaily, 7 February 2001. <www.sciencedaily.com/releases/2001/02/010206080603.htm>.
University Of Southern California. (2001, February 7). HIV/AIDS Researcher Announces New Protease Inhibitor; Holds Promise As A Medication With Fewer Side Effects And Once-Daily Dosing. ScienceDaily. Retrieved August 28, 2014 from www.sciencedaily.com/releases/2001/02/010206080603.htm
University Of Southern California. "HIV/AIDS Researcher Announces New Protease Inhibitor; Holds Promise As A Medication With Fewer Side Effects And Once-Daily Dosing." ScienceDaily. www.sciencedaily.com/releases/2001/02/010206080603.htm (accessed August 28, 2014).

Share This




More Health & Medicine News

Thursday, August 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Killer Amoeba Found in Louisiana Water System

Killer Amoeba Found in Louisiana Water System

AP (Aug. 28, 2014) State health officials say testing has confirmed the presence of a killer amoeba in a water system serving three St. John the Baptist Parish towns. (Aug. 28) Video provided by AP
Powered by NewsLook.com
Who Could Be Burnt by WHO's E-Cigs Move?

Who Could Be Burnt by WHO's E-Cigs Move?

Reuters - Business Video Online (Aug. 28, 2014) The World Health Organisation has called for the regulation of electronic cigarettes as both tobacco and medical products. Ciara Lee looks at the impact of the move on the tobacco industry. Video provided by Reuters
Powered by NewsLook.com
CDC Director On Ebola Outbreak: 'It's Worse Than I Feared'

CDC Director On Ebola Outbreak: 'It's Worse Than I Feared'

Newsy (Aug. 28, 2014) CDC director Tom Frieden says the Ebola outbreak is even worse than he feared. But he also said there's still hope to contain it. Video provided by Newsy
Powered by NewsLook.com
How A 'Rule Of Thumb' Could Slow Down Drinking

How A 'Rule Of Thumb' Could Slow Down Drinking

Newsy (Aug. 28, 2014) A study suggests people who follow a "rule of thumb" when pouring wine dispense less than those who don't have a particular amount in mind. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins